Filing Details
Liminatus Pharma, Inc. (NASDAQ:LIMN) filed a Form 8-K with the Securities and Exchange Commission on July 06, 2026, disclosing a material event.
8k filedNASDAQ:LIMN
Liminatus Pharma, Inc. (LIMN) Reports Material Event to SEC
Filing Details Liminatus Pharma, Inc. (NASDAQ:LIMN) filed a Form 8-K with the Securities and Exchange Commission on July 06, 2026, disclosing a material event. Market Context…
Market Context
Liminatus Pharma, Inc.'s stock currently trades at $0.14 with a market capitalization of $23.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Liminatus Pharma, Inc.'s stock.
All SEC filings for Liminatus Pharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View LIMN Stock Page
Frequently Asked Questions
Where can I read LIMN's SEC filings?
Browse all filings on our LIMN SEC filings page.
What types of SEC filings does Liminatus Pharma, Inc. file?
Public companies like Liminatus Pharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.